Savara Inc. Class Action Lawsuit Overview
Bragar Eagel & Squire, P.C., a leading law firm, has announced a class action lawsuit involving Savara Inc. This important legal action focuses on protecting the rights of investors who bought shares during a specific timeframe. If you’ve been affected, it’s crucial to understand your position and the next steps you should take.
Important Legal Dates and Investor Actions
For those who acquired securities in Savara from March 7, 2024, to May 23, 2025, the deadline to apply as a lead plaintiff is November 7, 2025. This is a critical date, and investors should not overlook their right to participate in these proceedings.
Details of the Allegations
During the period in question, Savara allegedly failed to disclose significant information regarding its biological product and the regulatory submission to the FDA. Investors were not adequately informed that the necessary details for the approval of its MOLBREEVI BLA were insufficient.
Impact on Stock Price
On May 27, 2025, after the company recognized the inadequacies in their application, they released a statement indicating the FDA's refusal to file due to incomplete information. This announcement led to a significant drop in Savara's stock price, highlighting the substantial financial impacts on shareholders.
What Investors Should Do
If you have faced financial loss due to your investments in Savara or have any relevant information, it’s advisable to connect with legal representatives. Bragar Eagel & Squire offers potential class members the opportunity for consultation on their legal rights in this ongoing situation.
Getting in Touch with Legal Advisors
Investors wishing to seek guidance or more information on the lawsuit can contact Brandon Walker or Marion Passmore directly. There is no obligation involved, and assistance is available regarding your rights as an investor or any further actions you can take.
About Bragar Eagel & Squire, P.C.
This law firm is well-known for its commitment to investor advocacy. Their team works diligently to represent individual and institutional investors across various legal matters, including commercial and securities litigation. For individuals seeking reliable legal representation and advice, Bragar Eagel & Squire stands as a robust option with a solid track record.
Frequently Asked Questions
What is the class action lawsuit against Savara about?
The class action lawsuit concerns allegations of undisclosed information related to Savara's product submissions to the FDA that led to financial losses for investors.
Who can participate in the class action?
Anyone who purchased or acquired Savara securities within the specified timeframe from March 7, 2024, to May 23, 2025, can apply to join the class action.
What is the deadline for filing?
The deadline to apply as a lead plaintiff in the class action lawsuit is November 7, 2025.
How has the stock price been affected?
After the FDA's announcement regarding the inadequacies of Savara's filing, the company's stock price experienced a notable decline of approximately 31.69%.
Who should I contact for more information?
For more information, investors can reach out to legal representatives at Bragar Eagel & Squire, P.C. via phone or email.
